Bio-Rad Laboratories, Inc.
Financials
Valuation Metrics
Bio-Rad Laboratories, Inc.'s Market Cap is $10.07B. At end of 2025 it was $8.17B. Ranked #900 of 3,121 in US market (top 29%), #614 of 1,658 on NYSE (top 37%), #62 of 205 in Health Care Equipment & Services (top 30%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $10.07B | US#900/3,121 Sec#62/205 |
| Revenue | $2.59B | US#1,289/3,121 Sec#81/205 |
| Net Income | $222M | US#1,240/3,121 Sec#60/205 |
| Total Assets | $10.25B | US#983/3,121 Sec#48/205 |
| Net Assets | $7.17B | US#550/3,121 Sec#33/205 |
| Employees | 7,450 | US#1,016/3,121 Sec#78/205 |
| Value | ||
| P/E | 45.26x | US#1,885/3,121 Sec#97/205 |
| P/B | 1.40x | US#811/3,121 Sec#41/205 |
| P/S | 3.89x | US#2,070/3,121 Sec#140/205 |
| EV/EBITDA | 20.11x | US#1,906/3,121 Sec#89/205 |
| FCF Yield | 3.51% | US#1,742/3,121 Sec#96/205 |
| Profitability | ||
| ROE | 3.10% | US#1,961/3,121 Sec#101/205 |
| ROA | 2.17% | US#1,600/3,121 Sec#97/205 |
| Op. Margin | 9.08% | US#1,674/3,121 Sec#86/205 |
| Revenue Growth | 1.37% | US#2,143/3,121 Sec#160/205 |
| Earnings Growth | -30.32% | US#1,636/3,121 Sec#84/205 |
| Financial Health | ||
| Debt Ratio | 42.91% | US#484/3,121 Sec#53/205 |
| Total Debt | $1.20B | US#1,447/3,121 Sec#78/205 |
| FCF | $353M | US#1,069/3,121 Sec#61/205 |
| Cash | $517M | US#1,055/3,121 Sec#58/205 |
| Current Ratio | 3.14x | US#753/3,121 Sec#74/205 |
| Net Debt/EBITDA | 1.28x | US#1,079/3,121 Sec#63/205 |
| Dividend | ||
| Div. Yield | 0.49% | US#1,542/3,121 Sec#43/205 |
| Performance | ||
| 1Y Return | 31.28% | US#775/3,121 Sec#66/205 |
| 1M Return | 3.25% | US#298/3,121 Sec#41/205 |
| From 52W High | -5.08% | US#192/3,121 Sec#26/205 |
| 1Y MDD | -28.86% | US#1,339/3,121 Sec#55/205 |
| Trading | ||
| Volume | 181,650 shares | US#2,737/3,121 Sec#189/205 |
| Trading Value | $69M | US#1,099/3,121 Sec#80/205 |
| Per Share | ||
| EPS | $8.31 | US#373/3,121 Sec#24/205 |
| BPS | $268.07 | US#15/3,121 Sec#1/205 |
Company Info
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.